| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/20/2007 | CA2284058C Diffusional implantable delivery system |
| 02/20/2007 | CA2283929C Method for treating headache pain with topical local anesthetic compositions |
| 02/20/2007 | CA2188567C Wet granulation formulation for bisphosphonic acids |
| 02/17/2007 | CA2556287A1 Methods of treatment using vascular occlusion in combination with one or more therapies |
| 02/15/2007 | WO2007019540A2 Controlled release alpha-lipoic acid formulation with an inositol compound |
| 02/15/2007 | WO2007019393A2 Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties |
| 02/15/2007 | WO2007019229A1 Compositions exhibiting improved flowability |
| 02/15/2007 | WO2007019224A2 Formulations and methods for enhancing the transdermal penetration of a drug |
| 02/15/2007 | WO2007019184A2 Oral suspension of prednisolone acetate |
| 02/15/2007 | WO2007019058A1 Tocopheryl polyethylene glycol succinate powder and process for preparing same |
| 02/15/2007 | WO2007018954A2 Application of a bioactive agent in a solvent composition to produce a target particle morphology |
| 02/15/2007 | WO2007018953A1 Preparation of nanoparticles |
| 02/15/2007 | WO2007018943A2 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 02/15/2007 | WO2007018887A2 Application of a bioactive agent to a substrate |
| 02/15/2007 | WO2007018885A2 A method for processing drugs |
| 02/15/2007 | WO2007018801A1 Gelled donepezil compositions and methods for making and using the same |
| 02/15/2007 | WO2007018710A1 Controlled release of hypnotic agents |
| 02/15/2007 | WO2007018659A1 Spot-on formulations for combating parasites |
| 02/15/2007 | WO2007018622A2 Vaginal treatment composition |
| 02/15/2007 | WO2007018607A2 Therapeutic uses of artificial nanostructures |
| 02/15/2007 | WO2007018588A1 Stable pharmaceutical composition comprising linezolid form iv |
| 02/15/2007 | WO2007018544A2 Tri-block copolymers for nanosphere-based drug delivery |
| 02/15/2007 | WO2007018275A1 Design of delivery medium based on rolling model |
| 02/15/2007 | WO2007018273A1 Composition for delivering diagnostic agent containing sugar-modified liposome |
| 02/15/2007 | WO2007018272A1 Sugar-modified liposome and composition for drug delivery containing the liposome |
| 02/15/2007 | WO2007018210A1 Adhesive patch less irritative to skin |
| 02/15/2007 | WO2007018192A1 Orally disintegratable tablet |
| 02/15/2007 | WO2007018190A1 Bitterness-reducing agent |
| 02/15/2007 | WO2007018147A1 Pharmaceutical titanium dioxide composite material of which pharmacological effect can be eliminated by light irradiation |
| 02/15/2007 | WO2007018057A1 Tablet rapidly disintegrating in the oral cavity and method of producing the same |
| 02/15/2007 | WO2007017905A1 Oral pharmaceutical suspension compositions of fexofenadine |
| 02/15/2007 | WO2007017875A2 Drug delivery system for topical administration |
| 02/15/2007 | WO2007017842A2 Satiety |
| 02/15/2007 | WO2007017712A1 Composition comprising polymeric, water-insoluble, anionic particles, processes and uses |
| 02/15/2007 | WO2007017514A1 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin |
| 02/15/2007 | WO2007017436A2 Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts |
| 02/15/2007 | WO2007017423A2 Pharmaceutical composition comprising a dpp-iv inhibitor |
| 02/15/2007 | WO2007017254A2 Method for production of particles of pharmaceutical substances collections of said particles and the use thereof |
| 02/15/2007 | WO2007017253A1 Oral preparation with controlled release of a benzenesulphonamide |
| 02/15/2007 | WO2007017249A1 Dosage forms with improved bioavailability |
| 02/15/2007 | WO2007017219A2 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility |
| 02/15/2007 | WO2007017196A2 Oil-in-water emulsions |
| 02/15/2007 | WO2007016948A1 Oral preparation with controlled release |
| 02/15/2007 | WO2007016791A1 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 02/15/2007 | WO2007016766A1 Transdermal drug delivery formulation |
| 02/15/2007 | WO2007016757A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 02/15/2007 | WO2006137855A3 Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility |
| 02/15/2007 | WO2006135693A3 Direct compression formulation of dpp-iv inhibitors and glitazones, and process |
| 02/15/2007 | WO2006135480A9 Oral pharmaceutical formulations comprising fenofibric acid and/or its salts |
| 02/15/2007 | WO2006131392A8 Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| 02/15/2007 | WO2006128937A3 Nanoparticles comprising chitosan and cyclodextrin |
| 02/15/2007 | WO2006123354A3 Oral pharmaceutical composition |
| 02/15/2007 | WO2006122925A3 Oral medicament based on a proton pump inhibitors |
| 02/15/2007 | WO2006106521A8 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
| 02/15/2007 | WO2006103638A3 Topical pharmaceutical compositions of terbinafine and processes for their preparation |
| 02/15/2007 | WO2006100087A3 Solid oral dosage form of valopi citabine (val-mcyd) and method of preparing it |
| 02/15/2007 | WO2006094737A3 Gastroresistant pharmaceutical formulations containing rifaximin |
| 02/15/2007 | WO2006085908A3 Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
| 02/15/2007 | WO2006071693A3 Injectable non-aqueous suspension |
| 02/15/2007 | WO2006071613A3 Injectable non-aqueous suspension |
| 02/15/2007 | WO2006068950A3 Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers |
| 02/15/2007 | WO2006065386A3 Methods for fabricating a drug delivery device |
| 02/15/2007 | WO2006050302A3 Dye-free pharmaceutical suspensions and related methods |
| 02/15/2007 | WO2006026713A3 Topical benfotiamine and pyridoxamine compositions |
| 02/15/2007 | WO2005105154A8 Polymer conjugate releasable under mild thiolytic conditions |
| 02/15/2007 | WO2005089472A3 Anti-adhesion spraying |
| 02/15/2007 | WO2005067583A3 Immunoliposome-nucleic acid amplication (ilnaa) assay |
| 02/15/2007 | WO2005000241A8 Compositons and methods for topical administration |
| 02/15/2007 | US20070037884 Novel succinate salt of O-desmethyl-venlafaxine |
| 02/15/2007 | US20070037880 administering a topical formulation containing ascorbic acid to a patient for treating vaginal infection; formulation is vaginally administered after completion of a standard treatment against bacterial, fungal or protozoarian infections; sustained release |
| 02/15/2007 | US20070037825 Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| 02/15/2007 | US20070037792 Pharmaceutical compositions |
| 02/15/2007 | US20070037782 Therapeutic agent for ageing macular degeneration |
| 02/15/2007 | US20070037765 gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 02/15/2007 | US20070037735 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/15/2007 | US20070036868 oily vitamin derivatives, gelling agent such as agarose, carrageenan and carrageenan-carob mixture, and protein, except gelatine; preparing solution or suspension, forming oil in water emulsion, adding to vegetable oil to for oil-water-oil emulsion, solidifying, cooling, drying |
| 02/15/2007 | US20070036867 Controlled and Sustained Gene Transfer Mediated by Thiol-Modified Polymers |
| 02/15/2007 | US20070036866 Cationic block copolymers |
| 02/15/2007 | US20070036865 Endosomolytic Polymers |
| 02/15/2007 | US20070036864 Hygeine product for mouth |
| 02/15/2007 | US20070036863 Oxacarbazepine film-coated tablets |
| 02/15/2007 | US20070036862 Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof |
| 02/15/2007 | US20070036861 Orally-dispersible multilayer tablet |
| 02/15/2007 | US20070036860 Treatment of allergic conditions |
| 02/15/2007 | US20070036859 Sustained release antihistamine and decongestant composition |
| 02/15/2007 | US20070036858 Drug delivery system for topical administration |
| 02/15/2007 | US20070036857 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin |
| 02/15/2007 | US20070036856 Diltiazem controlled release formulation and method of manufacture |
| 02/15/2007 | US20070036855 Soft polylactides |
| 02/15/2007 | US20070036854 Therapeutic applications of pro-apoptotic benzodiazepines |
| 02/15/2007 | US20070036853 Generally linear effervescent oral fentanyl dosage form and methods of administering |
| 02/15/2007 | US20070036852 Rapidly dispersing/disintegrating compositions |
| 02/15/2007 | US20070036851 Acid labile drug compositions |
| 02/15/2007 | US20070036850 Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound |
| 02/15/2007 | US20070036849 Use of phospholipid arachidonic acids for increasing muscle mass in humans |
| 02/15/2007 | US20070036848 Estrogen compositions and therapeutic methods of use thereof |
| 02/15/2007 | US20070036847 Lowly irritative adhesive patch |
| 02/15/2007 | US20070036845 Packeted body lotion towelette |
| 02/15/2007 | US20070036844 Porous materials having multi-size geometries |
| 02/15/2007 | US20070036843 Active agents complexed to ion-exchange resins or functional equivalents such as non-ionic, non-aqueous vehicles which allow the active agents to be stored in a vehicle ready for administration in a substantially anhydrous environment; storage stabilty |